JLE

Cahiers Santé Médecine Thérapeutique

MENU

Budd-Chiari syndrome: evolutionary profile? Volume 30, issue 5, Septembre-Octobre 2021

Figures


  • Figure 1

  • Figure 2

  • Figure 3

Tables

Authors
Service d’hépato-gastro-entérologie, CHU Hassan II Fès, Maroc
Faculté de médecine et de pharmacie, université Sidi Mohammed Ben Abdellah, Fés, Maroc
* Tirés à part

Budd-Chiari syndrome is defined by an obstruction of the hepatic blood circulation. The objective of this publication is to describe the epidemiological, clinical, biological, radiological, etiological and evolutionary data of patients with SBC followed at the Hassan II hospital center (CHU) in Fez during the period from January 2001 to June. 2018. During this period 1 503 cases of portal hypertension (HTP) were collected, of which 57 patients (3.7%) presented with SBC. The sex-ratio was 1, the average age is 35 years. The chronic form observed in 75% of cases. Acute presentation in 23% of cases, fulminant in 2%. Imaging had objectified the primary origin in 97% by thrombosis of the hepatic veins in 84% of the cases. The etiology of Budd-Chiari was related to an antithrombin III deficiency in 10%, and a protein S and C deficiency in 11%. Anticoagulants were administered in 90% of the cases. The evolution was marked by the development of HCC in 3%, hemorrhagic decompensation in 9%, refractory ascites in 18% and hepatic encephalopathy in 11%, so death was deplored in 10%. the mean follow-up was 30 months.